Symbols / LRMR $5.05 +5.43% Larimar Therapeutics, Inc.

Healthcare • Biotechnology • United States • NGM
LRMR Chart
About

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.

Fundamentals
Scroll to Statements
Sector Healthcare Industry Biotechnology Market Cap 524.61M
Enterprise Value 364.81M Income -165.67M Sales —
Book/sh 0.94 Cash/sh 1.32 Dividend Yield —
Payout 0.00% Employees 71 IPO —
P/E — Forward P/E -2.80 PEG —
P/S — P/B 5.37 P/C —
EV/EBITDA -2.12 EV/Sales — Quick Ratio 2.12
Current Ratio 2.19 Debt/Eq 5.21 LT Debt/Eq —
EPS (ttm) -2.27 EPS next Y -1.80 EPS Growth —
Revenue Growth — Earnings 2026-04-29 ROA -62.31%
ROE -132.59% ROIC — Gross Margin 0.00%
Oper. Margin 0.00% Profit Margin 0.00% Shs Outstand 103.88M
Shs Float 54.99M Short Float 9.68% Short Ratio 0.73
Short Interest — 52W High 6.42 52W Low 1.61
Beta 1.02 Avg Volume 4.29M Volume 2.01M
Target Price $16.70 Recom Strong_buy Prev Close $4.79
Price $5.05 Change 5.43%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$16.70
Mean price target
2. Current target
$5.05
Latest analyst target
3. DCF / Fair value
$-9.27
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$5.05
Low
$7.00
High
$26.00
Mean
$16.70

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-20 main Wedbush Outperform → Outperform $13
2026-03-03 main Wedbush Outperform → Outperform $12
2026-02-25 main Citigroup Buy → Buy $14
2026-02-25 reit Wedbush Outperform → Outperform $11
2025-10-02 main Oppenheimer Outperform → Outperform $21
2025-09-30 main Wedbush Outperform → Outperform $11
2025-09-30 main Baird Outperform → Outperform $7
2025-08-19 reit JMP Securities Market Outperform → Market Outperform $18
2025-08-15 main JMP Securities Market Outperform → Market Outperform $18
2025-06-25 reit Guggenheim Buy → Buy $26
2025-06-24 main Wedbush Outperform → Outperform $15
2025-06-24 reit Guggenheim Buy → Buy $26
2025-03-25 reit Guggenheim Buy → Buy $26
2025-03-25 main Baird Outperform → Outperform $10
2025-03-25 main HC Wainwright & Co. Buy → Buy $16
2025-01-29 init Truist Securities — → Buy $18
2025-01-24 reit HC Wainwright & Co. Buy → Buy $15
2024-12-17 reit HC Wainwright & Co. Buy → Buy $15
2024-12-16 reit HC Wainwright & Co. Buy → Buy $15
2024-11-18 reit HC Wainwright & Co. Buy → Buy $15
News
RSS: Latest LRMR news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-02-27 SHERMAN JEFFREY W Director — 5,000 $5.00 $25,000
2026-02-27 THOMAS FRANK E Director — 5,000 $5.00 $25,000
2026-02-27 FLYNN JAMES E Director and Beneficial Owner of more than 10% of a Class of Security — 5,000,000 $5.00 $25,000,000
2026-02-27 HAMILTON THOMAS EDWARD Director — 100,000 $5.00 $500,000
2026-01-26 BEN MAIMON CAROLE S Chief Executive Officer — 100,100 $0.00 $0
2026-01-26 CELANO MICHAEL Chief Financial Officer — 37,604 $0.00 $0
2026-01-26 CLAYTON RUSSELL Officer — 25,637 $0.00 $0
2026-01-26 SHANKAR GOPI Officer — 25,637 $0.00 $0
2025-07-31 FLYNN JAMES E Director and Beneficial Owner of more than 10% of a Class of Security — 9,375,000 $3.20 $30,000,000
2025-01-22 BEN MAIMON CAROLE S Chief Executive Officer — 91,000 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
172.50
+89.79%
90.89
+117.66%
41.76
+14.32%
36.53
Research And Development
154.22
+110.46%
73.28
+164.83%
27.67
+14.10%
24.25
Selling General And Administration
18.27
+3.75%
17.61
+25.01%
14.09
+14.76%
12.28
General And Administrative Expense
18.27
+3.75%
17.61
+25.01%
14.09
+14.76%
12.28
Other Gand A
18.27
+3.75%
17.61
+25.01%
14.09
+14.76%
12.28
Total Expenses
172.50
+89.79%
90.89
+117.66%
41.76
+14.32%
36.53
Operating Income
-172.50
-89.79%
-90.89
-117.66%
-41.76
-14.32%
-36.53
Total Operating Income As Reported
-172.50
-89.79%
-90.89
-117.66%
-41.76
-14.32%
-36.53
EBITDA
-172.15
-90.07%
-90.57
-118.52%
-41.45
-14.47%
-36.21
Normalized EBITDA
-172.15
-90.07%
-90.57
-118.52%
-41.45
-14.47%
-36.21
Reconciled Depreciation
0.35
+10.06%
0.32
+2.25%
0.31
-2.20%
0.32
EBIT
-172.50
-89.79%
-90.89
-117.66%
-41.76
-14.32%
-36.53
Net Income
-165.67
-105.54%
-80.60
-118.15%
-36.95
-4.51%
-35.35
Pretax Income
-165.67
-105.54%
-80.60
-118.15%
-36.95
-4.51%
-35.35
Other Income Expense
6.82
-33.66%
10.29
+113.89%
4.81
+310.67%
1.17
Other Non Operating Income Expenses
6.82
-33.66%
10.29
+113.89%
4.81
+310.67%
1.17
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-165.67
-105.54%
-80.60
-118.15%
-36.95
-4.51%
-35.35
Net Income From Continuing Operation Net Minority Interest
-165.67
-105.54%
-80.60
-118.15%
-36.95
-4.51%
-35.35
Net Income From Continuing And Discontinued Operation
-165.67
-105.54%
-80.60
-118.15%
-36.95
-4.51%
-35.35
Net Income Continuous Operations
-165.67
-105.54%
-80.60
-118.15%
-36.95
-4.51%
-35.35
Normalized Income
-165.67
-105.54%
-80.60
-118.15%
-36.95
-4.51%
-35.35
Net Income Common Stockholders
-165.67
-105.54%
-80.60
-118.15%
-36.95
-4.51%
-35.35
Diluted EPS
-2.27
-71.97%
-1.32
-57.14%
-0.84
+38.69%
-1.37
Basic EPS
-2.27
-71.97%
-1.32
-57.14%
-0.84
+38.69%
-1.37
Basic Average Shares
72.95
+19.09%
61.26
+39.53%
43.90
+70.41%
25.76
Diluted Average Shares
72.95
+19.09%
61.26
+39.53%
43.90
+70.41%
25.76
Diluted NI Availto Com Stockholders
-165.67
-105.54%
-80.60
-118.15%
-36.95
-4.51%
-35.35
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
145.84
-27.16%
200.22
+108.71%
95.94
-24.11%
126.41
Current Assets
142.02
-27.28%
195.30
+116.58%
90.17
-25.31%
120.74
Cash Cash Equivalents And Short Term Investments
136.85
-25.40%
183.45
+111.38%
86.79
-26.71%
118.43
Cash And Cash Equivalents
85.41
+157.13%
33.22
+24.18%
26.75
-0.28%
26.82
Cash Equivalents
—
26.70
+8.10%
24.70
+11.35%
22.18
Cash Financial
—
6.52
+218.16%
2.05
-55.87%
4.64
Other Short Term Investments
51.44
-65.76%
150.24
+150.22%
60.04
-34.46%
91.60
Receivables
0.75
-29.13%
1.05
+217.47%
0.33
0.00
Taxes Receivable
—
—
—
0.00
Accrued Interest Receivable
0.75
-29.13%
1.05
+217.47%
0.33
—
Prepaid Assets
4.17
-59.43%
10.28
+284.12%
2.68
+29.09%
2.07
Other Current Assets
0.25
-51.06%
0.52
+37.14%
0.38
+58.40%
0.24
Total Non Current Assets
3.82
-22.37%
4.92
-14.57%
5.76
+1.66%
5.67
Net PPE
2.69
-27.64%
3.72
-1.14%
3.76
+1.98%
3.69
Gross PPE
4.58
-12.88%
5.26
+5.51%
4.99
+8.34%
4.60
Accumulated Depreciation
-1.89
-22.68%
-1.54
-25.96%
-1.23
-34.03%
-0.91
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
0.69
+1.93%
0.67
+0.00%
0.67
+28.74%
0.52
Other Properties
3.81
-16.26%
4.54
+6.44%
4.27
+5.43%
4.05
Leases
0.09
+106.67%
0.04
+0.00%
0.04
+45.16%
0.03
Other Non Current Assets
1.13
-6.07%
1.20
-39.84%
2.00
+1.06%
1.98
Total Liabilities Net Minority Interest
67.76
+138.47%
28.41
+99.88%
14.21
-8.30%
15.50
Current Liabilities
64.80
+166.03%
24.36
+156.22%
9.51
-11.20%
10.71
Payables And Accrued Expenses
63.69
+173.39%
23.30
+168.73%
8.67
-14.12%
10.09
Payables
5.22
+115.18%
2.42
+88.93%
1.28
-23.90%
1.69
Accounts Payable
5.22
+115.18%
2.42
+88.93%
1.28
-23.90%
1.69
Current Accrued Expenses
58.47
+180.16%
20.87
+182.59%
7.39
-12.16%
8.41
Current Debt And Capital Lease Obligation
1.10
+4.25%
1.06
+26.64%
0.84
+36.99%
0.61
Current Capital Lease Obligation
1.10
+4.25%
1.06
+26.64%
0.84
+36.99%
0.61
Total Non Current Liabilities Net Minority Interest
2.96
-26.99%
4.06
-13.85%
4.71
-1.83%
4.80
Long Term Debt And Capital Lease Obligation
2.96
-26.99%
4.06
-13.85%
4.71
-1.83%
4.80
Long Term Capital Lease Obligation
2.96
-26.99%
4.06
-13.85%
4.71
-1.83%
4.80
Stockholders Equity
78.08
-54.55%
171.81
+110.24%
81.72
-26.31%
110.90
Common Stock Equity
78.08
-54.55%
171.81
+110.24%
81.72
-26.31%
110.90
Capital Stock
0.08
+29.69%
0.06
+48.84%
0.04
+0.00%
0.04
Common Stock
0.08
+29.69%
0.06
+48.84%
0.04
+0.00%
0.04
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
83.09
+30.20%
63.82
+45.33%
43.91
+1.48%
43.27
Ordinary Shares Number
83.09
+30.20%
63.82
+45.33%
43.91
+1.48%
43.27
Additional Paid In Capital
512.78
+16.34%
440.76
+63.15%
270.15
+2.92%
262.50
Retained Earnings
-434.83
-61.55%
-269.16
-42.75%
-188.55
-24.37%
-151.60
Gains Losses Not Affecting Retained Earnings
0.05
-63.51%
0.15
+82.72%
0.08
+361.29%
-0.03
Other Equity Adjustments
0.05
-63.51%
0.15
+82.72%
0.08
+361.29%
-0.03
Total Equity Gross Minority Interest
78.08
-54.55%
171.81
+110.24%
81.72
-26.31%
110.90
Total Capitalization
78.08
-54.55%
171.81
+110.24%
81.72
-26.31%
110.90
Working Capital
77.23
-54.82%
170.95
+111.91%
80.67
-26.69%
110.03
Invested Capital
78.08
-54.55%
171.81
+110.24%
81.72
-26.31%
110.90
Total Debt
4.07
-20.52%
5.12
-7.74%
5.55
+2.55%
5.41
Capital Lease Obligations
4.07
-20.52%
5.12
-7.74%
5.55
+2.55%
5.41
Net Tangible Assets
78.08
-54.55%
171.81
+110.24%
81.72
-26.31%
110.90
Tangible Book Value
78.08
-54.55%
171.81
+110.24%
81.72
-26.31%
110.90
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-113.20
-59.98%
-70.76
-111.48%
-33.46
-21.36%
-27.57
Cash Flow From Continuing Operating Activities
-113.20
-59.98%
-70.76
-111.48%
-33.46
-21.36%
-27.57
Net Income From Continuing Operations
-165.67
-105.54%
-80.60
-118.15%
-36.95
-4.51%
-35.35
Depreciation Amortization Depletion
0.35
+10.06%
0.32
+2.25%
0.31
-2.20%
0.32
Depreciation
0.35
+10.06%
0.32
+2.25%
0.31
-2.20%
0.32
Depreciation And Amortization
0.35
+10.06%
0.32
+2.25%
0.31
-2.20%
0.32
Other Non Cash Items
-0.28
-48.68%
-0.19
-130.49%
-0.08
-78.26%
-0.05
Stock Based Compensation
7.00
-20.37%
8.80
+15.51%
7.62
+15.05%
6.62
Operating Gains Losses
—
—
—
—
Gain Loss On Sale Of PPE
—
—
—
0.00
Change In Working Capital
47.10
+662.70%
6.17
+345.92%
-2.51
-250.45%
1.67
Change In Prepaid Assets
6.68
+178.91%
-8.46
-694.84%
-1.06
-422.06%
-0.20
Change In Payables And Accrued Expense
40.34
+176.76%
14.58
+1122.95%
-1.43
-177.36%
1.84
Change In Accrued Expense
37.55
+179.49%
13.44
+1414.68%
-1.02
-156.28%
1.82
Change In Payable
2.79
+144.70%
1.14
+383.13%
-0.40
-1650.00%
0.03
Change In Account Payable
2.79
+144.70%
1.14
+383.13%
-0.40
-1650.00%
0.03
Change In Other Current Assets
0.07
+15.87%
0.06
+400.00%
-0.02
-167.74%
0.03
Change In Other Current Liabilities
—
—
—
—
Investing Cash Flow
100.31
+217.48%
-85.39
-356.01%
33.35
+136.67%
-90.96
Cash Flow From Continuing Investing Activities
100.31
+217.48%
-85.39
-356.01%
33.35
+136.67%
-90.96
Net PPE Purchase And Sale
-0.09
+82.33%
-0.52
-214.02%
-0.16
-64.00%
-0.10
Purchase Of PPE
-0.09
+82.33%
-0.52
-214.02%
-0.16
-64.00%
-0.10
Capital Expenditure
-0.09
+82.33%
-0.52
-214.02%
-0.16
-64.00%
-0.10
Net Investment Purchase And Sale
100.40
+218.30%
-84.87
-353.22%
33.52
+136.89%
-90.86
Purchase Of Investment
-83.60
+63.31%
-227.87
-125.10%
-101.23
+24.23%
-133.61
Sale Of Investment
184.00
+28.67%
143.00
+6.12%
134.75
+215.20%
42.75
Net Business Purchase And Sale
—
—
—
—
Purchase Of Business
—
—
—
—
Financing Cash Flow
65.09
-59.79%
161.88
+539510.00%
0.03
-99.96%
75.26
Cash Flow From Continuing Financing Activities
65.09
-59.79%
161.88
+539510.00%
0.03
-99.96%
75.26
Net Common Stock Issuance
65.09
-59.78%
161.81
0.00
-100.00%
75.26
Proceeds From Stock Option Exercised
0.00
-100.00%
0.08
+156.67%
0.03
0.00
Changes In Cash
52.19
+809.94%
5.74
+7647.37%
-0.08
+99.82%
-43.27
Beginning Cash Position
33.82
+20.42%
28.09
-0.27%
28.16
-60.57%
71.44
End Cash Position
86.02
+154.31%
33.82
+20.42%
28.09
-0.27%
28.16
Free Cash Flow
-113.29
-58.95%
-71.28
-111.98%
-33.62
-21.52%
-27.67
Amortization Of Securities
-1.70
+67.69%
-5.26
-185.19%
-1.84
-138.11%
-0.77
Common Stock Issuance
65.09
-59.78%
161.81
0.00
-100.00%
75.26
Issuance Of Capital Stock
65.09
-59.78%
161.81
0.00
-100.00%
75.26
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category